NEW YORK (GenomeWeb) – Sygnis said this week that it has completed its acquisition of Innova Biosciences, a privately held UK-based bioconjugates company. Sygnis paid €10.8 million ($12.2 million), consisting of €8 million in cash and 2 million shares of Sygnis as a contribution in kind. Depending on agreed performance indicators, the purchase price will also include up to 1.5 million shares issued as convertible bonds. Innova develops, manufactures and commercializes labelling reagents, including its Lightning Link labeling technology.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.